Hydrogen sulfide small intestinal bacterial overgrowth case registry - Goldenberg, Joshua Z; Nevitt, Britta; Wentz, Anna E; Bradley, Ryan; Siebecker, Allison (medRxiv, 2023)
Background There is growing interest in hydrogen sulfide small intestinal bacterial overgrowth (H2S SIBO). However, basic questions including how clinicians are making the diagnosis, what symptoms are present, and what clinicians are using for treatment, remain unanswered.Aims To address this, we created an online, survey-based, clinical registry of H2S SIBO cases.Methods Participants in this study were clinicians diagnosing and treating patients with H2S SIBO and input data on patient presentation, diagnosis, treatment, and treatment response. We describe the population and summarize our results using descriptive statistics. We use Pearson’s chi-squared test and modified Poisson regression in exploratory analyses.Results 131 total cases were submitted by 99 providers across a spectrum of health disciplines. The mean patient age was 45.6 (71.4% female). The most common symptoms were bloating (77.0%), constipation (50.8%) and abdominal pain (50.8%). Diagnosis was made based on flatline hydrogen in the 3rd hour of a lactulose breath test (42.5%), symptom presentation (empiric) (31.9%), or H2S levels (25.7%). The most common treatments used were a low sulfur diet (46.6%), oregano (44.0%), and bismuth (39.7%). Fifty-eight percent of cases were responders. Of the most common interventions used, only a low sulfur diet (73% responder; p=0.01) and bismuth (76% responder; p=0.01) were significantly associated with treatment response. Interestingly, response rates differed based on how H2S SIBO was diagnosed, with empiric underperforming flatline diagnoses (relative risk 0.60; p=0.04).Conclusions This case registry represents the largest collection of H2S SIBO cases to-date, providing important early descriptive information on this emerging diagnosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by individual donors, the Gastroenterology Association of Naturopathic Physicians, and in-kind donation from the Helfgott Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was reviewed and approved for exemption status by the institutional review board of the National University of Natural Medicine (registration number JG41321). Informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request and IRB approval.